Pulmonary hypertension in COPD: results from the ASPIRE registry.

PubWeight™: 1.16‹?› | Rank: Top 10%

🔗 View Article (PMID 23018917)

Published in Eur Respir J on September 27, 2012

Authors

Judith Hurdman1, Robin Condliffe, Charlie A Elliot, Andrew Swift, Smitha Rajaram, Christine Davies, Catherine Hill, Neil Hamilton, Iain J Armstrong, Catherine Billings, Lauren Pollard, Jim M Wild, Allan Lawrie, Rod Lawson, Ian Sabroe, David G Kiely

Author Affiliations

1: Sheffield Pulmonary Vascular Disease Unit, Royal Hallamshire Hospital, Sheffield, UK.

Articles citing this

CT scan-measured pulmonary artery to aorta ratio and echocardiography for detecting pulmonary hypertension in severe COPD. Chest (2014) 1.17

The Saudi Guidelines for the Diagnosis and Management of COPD. Ann Thorac Med (2014) 0.92

Pathophysiology and clinical implications of pulmonary arterial enlargement in COPD. Int J Chron Obstruct Pulmon Dis (2013) 0.90

Four cases with group 3 out-of-proportion pulmonary hypertension with a favorable response to vasodilators. Respir Med Case Rep (2013) 0.85

Pulmonary Hypertension in Patients with Chronic Fibrosing Idiopathic Interstitial Pneumonias. PLoS One (2015) 0.83

Pulmonary hypertension and right heart dysfunction in chronic lung disease. Biomed Res Int (2014) 0.82

Lung transplantation in chronic obstructive pulmonary disease: patient selection and special considerations. Int J Chron Obstruct Pulmon Dis (2015) 0.80

Diagnosis, assessment, and phenotyping of COPD: beyond FEV1. Int J Chron Obstruct Pulmon Dis (2016) 0.80

Pharmacotherapies for COPD. Clin Med Insights Circ Respir Pulm Med (2013) 0.79

Morphological changes in small pulmonary vessels are associated with severe acute exacerbation in chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis (2016) 0.78

Study design and rationale for investigating phosphodiesterase type 5 inhibition for the treatment of pulmonary hypertension due to chronic obstructive lung disease: the TADA-PHiLD (TADAlafil for Pulmonary Hypertension associated with chronic obstructive Lung Disease) trial. Pulm Circ (2013) 0.78

Electrocardiographic differences between COPD patients evaluated for lung transplantation with and without pulmonary hypertension. COPD (2014) 0.76

Clinical variability of respiratory pulmonary hypertension: implications for diagnosis and management. Multidiscip Respir Med (2013) 0.76

Vasodilatory effect of the stable vasoactive intestinal peptide analog RO 25-1553 in murine and rat lungs. PLoS One (2013) 0.76

The role of phosphodiesterase inhibitors in the management of pulmonary vascular diseases. Glob Cardiol Sci Pract (2014) 0.76

Pulmonary hemodynamic profile in chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis (2015) 0.75

The effects of pulmonary vasodilating agents on right ventricular parameters in severe group 3 pulmonary hypertension: a pilot study. Pulm Circ (2016) 0.75

Pulmonary vascular and ventricular dysfunction in the susceptible patient (2015 Grover Conference series). Pulm Circ (2016) 0.75

A diffuse lung emphysema, severe pulmonary hypertension and lack of airflow limitation. Respir Med Case Rep (2017) 0.75

Impact of High-Intensity-NIV on the heart in stable COPD: a randomised cross-over pilot study. Respir Res (2017) 0.75

Implications of the pulmonary artery to ascending aortic ratio in patients with relatively mild chronic obstructive pulmonary disease. J Thorac Dis (2016) 0.75

Functional and Prognostic Implications of the Main Pulmonary Artery Diameter to Aorta Diameter Ratio from Chest Computed Tomography in Korean COPD Patients. PLoS One (2016) 0.75

Healthcare burden of pulmonary hypertension owing to lung disease and/or hypoxia. BMC Pulm Med (2017) 0.75

Pulmonary hypertension in the elderly: a different disease? Breathe (Sheff) (2016) 0.75

EXPRESS: PULMONARY VENOUS REMODELING IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE AND IDIOPATHIC PULMONARY ARTERIAL HYPERTENSION. Pulm Circ (2017) 0.75

Articles by these authors

Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet (2012) 41.47

Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet (2012) 26.95

Prediction of cancer outcome with microarrays: a multiple random validation strategy. Lancet (2005) 17.75

Does the CONSORT checklist improve the quality of reports of randomised controlled trials? A systematic review. Med J Aust (2006) 11.40

Single, rapid coastal settlement of Asia revealed by analysis of complete mitochondrial genomes. Science (2005) 6.86

Bone marrow edema and its relation to progression of knee osteoarthritis. Ann Intern Med (2003) 4.98

Inhaled iloprost for severe pulmonary hypertension. N Engl J Med (2002) 3.90

Connective tissue disease-associated pulmonary arterial hypertension in the modern treatment era. Am J Respir Crit Care Med (2008) 3.67

Quantification of regional fractional ventilation in human subjects by measurement of hyperpolarized 3He washout with 2D and 3D MRI. J Appl Physiol (1985) (2013) 2.79

Changing demographics, epidemiology, and survival of incident pulmonary arterial hypertension: results from the pulmonary hypertension registry of the United Kingdom and Ireland. Am J Respir Crit Care Med (2012) 2.00

TNF-related apoptosis-inducing ligand (TRAIL) regulates inflammatory neutrophil apoptosis and enhances resolution of inflammation. J Leukoc Biol (2011) 1.98

Increased risk of stroke after discontinuation of acetylsalicylic acid: a UK primary care study. Neurology (2011) 1.97

[Drugs and cancer risk: the example of THM]. Rev Prat (2013) 1.97

Tolerance to microbial TLR ligands: molecular mechanisms and relevance to disease. J Endotoxin Res (2006) 1.86

Systematic review of the epidemiology of complicated peptic ulcer disease: incidence, recurrence, risk factors and mortality. Digestion (2011) 1.80

Functional MRI of the lung using hyperpolarized 3-helium gas. J Magn Reson Imaging (2004) 1.76

Climate change and postglacial human dispersals in southeast Asia. Mol Biol Evol (2008) 1.74

Bosentan in pulmonary hypertension associated with fibrotic idiopathic interstitial pneumonia. Am J Respir Crit Care Med (2014) 1.73

Estimates of the cancer burden in Europe from radioactive fallout from the Chernobyl accident. Int J Cancer (2006) 1.71

Comparison of the diagnostic utility of cardiac magnetic resonance imaging, computed tomography, and echocardiography in assessment of suspected pulmonary arterial hypertension in patients with connective tissue disease. J Rheumatol (2012) 1.68

Ancient voyaging and Polynesian origins. Am J Hum Genet (2011) 1.65

The effect of helium and oxygen on exercise performance in chronic obstructive pulmonary disease: a randomized crossover trial. Am J Respir Crit Care Med (2006) 1.65

Predicting corticosteroid response in chronic obstructive pulmonary disease using exhaled nitric oxide. Am J Respir Crit Care Med (2009) 1.60

MRI of helium-3 gas in healthy lungs: posture related variations of alveolar size. J Magn Reson Imaging (2004) 1.57

Alcohol-attributable mortality in France. Eur J Public Health (2013) 1.57

Anthracyclines, mitoxantrone, radiotherapy, and granulocyte colony-stimulating factor: risk factors for leukemia and myelodysplastic syndrome after breast cancer. J Clin Oncol (2006) 1.56

Analgesic effect of auricular acupuncture for cancer pain: a randomized, blinded, controlled trial. J Clin Oncol (2003) 1.55

emPHasis-10: development of a health-related quality of life measure in pulmonary hypertension. Eur Respir J (2013) 1.52

Improved outcomes in medically and surgically treated chronic thromboembolic pulmonary hypertension. Am J Respir Crit Care Med (2008) 1.52

Emphysematous changes and normal variation in smokers and COPD patients using diffusion 3He MRI. Eur J Radiol (2005) 1.50

Hypoxia-inducible factor 2α regulates key neutrophil functions in humans, mice, and zebrafish. Blood (2013) 1.48

Prolyl hydroxylase 3 (PHD3) is essential for hypoxic regulation of neutrophilic inflammation in humans and mice. J Clin Invest (2011) 1.44

Using transcutaneous carbon dioxide monitor (TOSCA 500) to detect respiratory failure in patients with amyotrophic lateral sclerosis: a validation study. Amyotroph Lateral Scler (2012) 1.43

Direct visualisation of collateral ventilation in COPD with hyperpolarised gas MRI. Thorax (2012) 1.42

Clinical trials in childhood acute lymphoblastic leukemia: a common prognostic classification and a common induction therapy are now warranted. J Pediatr Hematol Oncol (2002) 1.39

COPD causation and workplace exposures: an assessment of agreement among expert clinical raters. COPD (2013) 1.39

The role of interleukin-8 and its receptors in inflammatory lung disease: implications for therapy. Am J Respir Med (2002) 1.38

Risk of secondary leukemia after a solid tumor in childhood according to the dose of epipodophyllotoxins and anthracyclines: a case-control study by the Société Française d'Oncologie Pédiatrique. J Clin Oncol (2003) 1.36

Eotaxin (CCL11) and eotaxin-2 (CCL24) induce recruitment of eosinophils, basophils, neutrophils, and macrophages as well as features of early- and late-phase allergic reactions following cutaneous injection in human atopic and nonatopic volunteers. J Immunol (2002) 1.35

Oral treprostinil for the treatment of pulmonary arterial hypertension in patients receiving background endothelin receptor antagonist and phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C2 study): a randomized controlled trial. Chest (2013) 1.31

Training faculty to facilitate communication skills training: development and evaluation of a workshop. Patient Educ Couns (2008) 1.31

Combined helium-3/proton magnetic resonance imaging measurement of ventilated lung volumes in smokers compared to never-smokers. J Magn Reson Imaging (2005) 1.31

Pulmonary artery relative area change detects mild elevations in pulmonary vascular resistance and predicts adverse outcome in pulmonary hypertension. Invest Radiol (2012) 1.30

Cooperative molecular and cellular networks regulate Toll-like receptor-dependent inflammatory responses. FASEB J (2006) 1.30

Dynamic radial projection MRI of inhaled hyperpolarized 3He gas. Magn Reson Med (2003) 1.28

The expression and roles of Toll-like receptors in the biology of the human neutrophil. J Leukoc Biol (2005) 1.26

Agonists of toll-like receptor (TLR)2 and TLR4 are unable to modulate platelet activation by adenosine diphosphate and platelet activating factor. Thromb Haemost (2005) 1.23

Costello syndrome associated with novel germline HRAS mutations: an attenuated phenotype? Am J Med Genet A (2008) 1.21

Episiotomy rates around the world: an update. Birth (2005) 1.19

The influence of lung airways branching structure and diffusion time on measurements and models of short-range 3He gas MR diffusion. J Magn Reson (2012) 1.19

Agonists of toll-like receptors 2 and 4 activate airway smooth muscle via mononuclear leukocytes. Am J Respir Crit Care Med (2005) 1.16

The role of TLRs in neutrophil activation. Curr Opin Pharmacol (2011) 1.15

Toll-like receptor (TLR)2 and TLR4 agonists regulate CCR expression in human monocytic cells. J Immunol (2004) 1.12

Ontario doctors' attitudes toward and use of clinical practice guidelines in oncology. J Eval Clin Pract (2007) 1.12

Inhibition of neutrophil apoptosis by ATP is mediated by the P2Y11 receptor. J Immunol (2007) 1.12

Interleukin-1β regulates CXCL8 release and influences disease outcome in response to Streptococcus pneumoniae, defining intercellular cooperation between pulmonary epithelial cells and macrophages. Infect Immun (2011) 1.11

Reduced microRNA-150 is associated with poor survival in pulmonary arterial hypertension. Am J Respir Crit Care Med (2012) 1.11

Feasibility of image registration and intensity-modulated radiotherapy planning with hyperpolarized helium-3 magnetic resonance imaging for non-small-cell lung cancer. Int J Radiat Oncol Biol Phys (2007) 1.09

Effective caspase inhibition blocks neutrophil apoptosis and reveals Mcl-1 as both a regulator and a target of neutrophil caspase activation. PLoS One (2011) 1.08

A study of the cough reflex in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med (2003) 1.07

"Dirty little secrets"--endotoxin contamination of recombinant proteins. Immunol Lett (2006) 1.06

Temporal interleukin-1beta secretion from primary human peripheral blood monocytes by P2X7-independent and P2X7-dependent mechanisms. J Biol Chem (2010) 1.05

Contribution of record linkage to vital status determination in cancer patients. Stud Health Technol Inform (2009) 1.04

Contrary prostaglandins: the opposing roles of PGD2 and its metabolites in leukocyte function. J Leukoc Biol (2006) 1.04

S100A4 and bone morphogenetic protein-2 codependently induce vascular smooth muscle cell migration via phospho-extracellular signal-regulated kinase and chloride intracellular channel 4. Circ Res (2009) 1.04

Granulocyte apoptosis in the pathogenesis and resolution of lung disease. Clin Sci (Lond) (2006) 1.03

Compressed sensing in hyperpolarized 3He lung MRI. Magn Reson Med (2010) 1.03

Impairment of apoptotic cell engulfment by pyocyanin, a toxic metabolite of Pseudomonas aeruginosa. Am J Respir Crit Care Med (2007) 1.03

Quantitative analysis of regional airways obstruction using dynamic hyperpolarized 3He MRI-preliminary results in children with cystic fibrosis. J Magn Reson Imaging (2005) 1.02

Subversion of a lysosomal pathway regulating neutrophil apoptosis by a major bacterial toxin, pyocyanin. J Immunol (2008) 1.01

Management of an incidentally discovered pulmonary nodule. Eur Radiol (2006) 1.01

Hyperpolarized 3helium magnetic resonance ventilation imaging of the lung in cystic fibrosis: comparison with high resolution CT and spirometry. Eur Radiol (2006) 1.01

A Bayesian approach to copy-number-polymorphism analysis in nuclear pedigrees. Am J Hum Genet (2007) 1.01

Finite-difference simulations of 3He diffusion in 3D alveolar ducts: comparison with the "cylinder model". Magn Reson Med (2004) 1.01

A graphical method for exploring heterogeneity in meta-analyses: application to a meta-analysis of 65 trials. Stat Med (2002) 1.01

Delta 12-prostaglandin J2, a plasma metabolite of prostaglandin D2, causes eosinophil mobilization from the bone marrow and primes eosinophils for chemotaxis. J Immunol (2003) 1.01

The role of interleukin-1beta in direct and toll-like receptor 4-mediated neutrophil activation and survival. Am J Pathol (2004) 0.99

CCR4 in human allergen-induced late responses in the skin and lung. Eur J Immunol (2002) 0.99

Diagnostic accuracy of cardiovascular magnetic resonance imaging of right ventricular morphology and function in the assessment of suspected pulmonary hypertension results from the ASPIRE registry. J Cardiovasc Magn Reson (2012) 0.98